The demo accomplished both its Most important endpoints, with semaglutide 2.4 mg demonstrating statistically sizeable and outstanding advancements in liver fibrosis without having worsening of steatohepatitis, together with resolution of steatohepatitis without worsening of liver fibrosis in people